Latest Diet Drug Enthusiasm Likely to be Short-Lived

Agenda-Setting Financial Insight.
July 18 2012 4:46 PM

Latest Diet Drug Enthusiasm Likely to be Short-Lived

137165925
The latest surge of drug enthusiasm may last about as long as the typical diet.

Photo by PHILIPPE HUGUEN/AFP/Getty Images

Two U.S. biotech firms are bingeing on obesity drugs. Their concoctions for weight loss have both been approved by the Food and Drug Administration in the last month. With American obesity rates rocketing, analysts are eyeing fat sales and bankers are weighing mergers. 

Vivus, one of the producers, just got the OK for its drug Qsymia. The company’s market value has more than tripled since January to over $3 billion. Meanwhile the value of Arena Pharmaceuticals, whose Belviq was approved last month, has gone up five-fold. 

Yet it’s a stretch to think Vivus will ever sell $3.6 billion-worth of its drug every year, as Jefferies forecasts. In tests, users only lost 10 percent of their weight. Qsymia is composed of two cheap generic drugs already on the market, so doctors may just prescribe them separately. And side effects, such as an increased risk of birth defects, will probably limit sales. 

A big problem for all diet pills is that in the context of human history obesity has only very recently become, for some people, a bigger threat than starvation. There are good reasons why it’s difficult to curtail appetite or calorie absorption significantly. 

That’s one reason diet aids don’t often live up to expectations. Analysts thought GlaxoSmithKline’s Alli would bring in about $2 billion of annual sales, but customers never warmed to the incontinence-inducing product and sales are running much lower. Procter & Gamble’s fat substitute Olestra similarly raised expectations and then dashed them. 

Side-effects are another concern. Sanofi thought it could sell $3 billion of Acomplia per year, but withdrew the drug when it was linked to an increased risk of suicide. Abbott pulled Meridia due to the chance of stroke. And Wyeth took a charge in excess of $20 billion for lawsuits arising from its notorious fen-phen combination. 

Obesity is a serious problem for a growing number of people. And the new drugs may yet prove effective and safe enough that users stick with them. But the odds aren’t great. The biotechs may be smart, but tens of thousands of years of evolution have honed people’s appetite for the Baconator. The latest surge of drug enthusiasm may last about as long as the typical diet.

Read more at Reuters Breakingviews.

Advertisement

Robert Cyran moved from the London office to New York, where he covers global technology, pharmaceuticals and special situations. Rob began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine.

TODAY IN SLATE

Foreigners

More Than Scottish Pride

Scotland’s referendum isn’t about nationalism. It’s about a system that failed, and a new generation looking to take a chance on itself. 

What Charles Barkley Gets Wrong About Corporal Punishment and Black Culture

Why Greenland’s “Dark Snow” Should Worry You

Three Talented Actresses in Three Terrible New Shows

Why Do Some People See the Virgin Mary in Grilled Cheese?

The science that explains the human need to find meaning in coincidences.

Jurisprudence

Happy Constitution Day!

Too bad it’s almost certainly unconstitutional.

Is It Worth Paying Full Price for the iPhone 6 to Keep Your Unlimited Data Plan? We Crunch the Numbers.

What to Do if You Literally Get a Bug in Your Ear

  News & Politics
Weigel
Sept. 16 2014 7:03 PM Kansas Secretary of State Loses Battle to Protect Senator From Tough Race
  Business
Moneybox
Sept. 16 2014 4:16 PM The iPhone 6 Marks a Fresh Chance for Wireless Carriers to Kill Your Unlimited Data
  Life
The Eye
Sept. 16 2014 12:20 PM These Outdoor Cat Shelters Have More Style Than the Average Home
  Double X
The XX Factor
Sept. 15 2014 3:31 PM My Year As an Abortion Doula
  Slate Plus
Slate Plus Video
Sept. 16 2014 2:06 PM A Farewell From Emily Bazelon The former senior editor talks about her very first Slate pitch and says goodbye to the magazine.
  Arts
Brow Beat
Sept. 16 2014 8:43 PM This 17-Minute Tribute to David Fincher Is the Perfect Preparation for Gone Girl
  Technology
Future Tense
Sept. 16 2014 6:40 PM This iPhone 6 Feature Will Change Weather Forecasting
  Health & Science
Medical Examiner
Sept. 16 2014 11:46 PM The Scariest Campfire Story More horrifying than bears, snakes, or hook-handed killers.
  Sports
Sports Nut
Sept. 15 2014 9:05 PM Giving Up on Goodell How the NFL lost the trust of its most loyal reporters.